GlassScriptPhysician profile
Robert P Chiascione
NPI 1710935697
$174,231.25
in general payments reported to CMS, 2019-2025
62 companies · $48K in 2025
The $48K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,377 · 2020: $2,614 · 2021: $13K · 2022: $26K · 2023: $33K · 2024: $48K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $115K · Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $115,439.79 |
| Food and Beverage | $13,569.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $145,704.28 | 2019-2025 | |
| Abbvie INC. | $4,733.49 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $3,724.66 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,461.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,535.54 | 2019-2025 | Jardiance, Synjardy, Jascayd |
| Glaxosmithkline, LLC. | $1,523.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $1,463.54 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $1,178.30 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $1,119.41 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $1,083.69 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,064.70 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $795.57 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $700.85 | 2022-2025 | |
| Pfizer INC. | $679.21 | 2019-2025 | |
| Abbott Laboratories | $481.91 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chiascione listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.